Literature DB >> 1379409

Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies.

E Nobile-Orazio1, S Barbieri, L Baldini, P Marmiroli, M Carpo, S Premoselli, E Manfredini, G Scarlato.   

Abstract

In an unselected series of patients with monoclonal gammopathy of undetermined significance (MGUS) we found neuropathy in 2 of 34 patients with IgG (6%), 2 of 14 with IgA (14%), and 8 of 26 with IgM MGUS (31%). The neuropathy was subclinical in 6 patients (1 IgG, 1 IgA, and 4 IgM). Patients with IgG or IgA MGUS had a prominent motor impairment with electrophysiologic and morphologic findings suggestive of predominant axonal degeneration. No deposit of the M-protein in sural nerve and no reactivity of the M-protein with nerve was detected in these patients. Patients with IgM MGUS had a prominent sensory impairment with evidence of predominant demyelination. In 6 of these patients the M-protein reacted with the myelin-associated glycoprotein (MAG). The higher prevalence of neuropathy in patients with IgM MGUS may be related to the frequent reactivity of IgM M-proteins with MAG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379409     DOI: 10.1111/j.1600-0404.1992.tb06033.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  16 in total

Review 1.  Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Authors:  Hafsa M Chaudhry; Michelle L Mauermann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

Review 2.  Advances in the Treatment of Paraproteinemic Neuropathy.

Authors:  Eduardo Nobile-Orazio; Mariangela Bianco; Andrea Nozza
Journal:  Curr Treat Options Neurol       Date:  2017-10-16       Impact factor: 3.598

3.  Axonal neuropathy associated with monoclonal gammopathy of undetermined significance.

Authors:  K C Gorson; A H Ropper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

Review 4.  An update on monoclonal gammopathy and neuropathy.

Authors:  Sindhu Ramchandren; Richard A Lewis
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

5.  Myelin protein zero is naturally processed in the B cells of monoclonal gammopathy of undetermined significance of immunoglobulin M isotype: aberrant triggering of a patient's T cells.

Authors:  Eva Hellqvist; Maria Kvarnström; Anita Söderberg; Magnus Vrethem; Jan Ernerudh; Anders Rosén
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

6.  Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.

Authors:  John P Bida; Robert A Kyle; Terry M Therneau; L Joseph Melton; Matthew F Plevak; Dirk R Larson; Angela Dispenzieri; Jerry A Katzmann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2009-08       Impact factor: 7.616

7.  Distinct lymphocytes subsets in IgM-related neuropathy: clinical-immunological correlations.

Authors:  Raffaele Iorio; Mario Sabatelli; Alessandra Del Grande; Giulia Bisogni; Valentina Damato; Domenico Plantone; Alessandro Marti; Giovanni Frisullo; Angela Romano; Paolo Maria Rossini; Marco Luigetti
Journal:  Neurol Sci       Date:  2014-09-06       Impact factor: 3.307

8.  Warfarin improves neuropathy in monoclonal gammopathy of undetermined significance.

Authors:  Teny Henry Gomez; Beata Holkova; Danielle Noreika; Egidio Del Fabbro
Journal:  BMJ Case Rep       Date:  2016-06-17

Review 9.  Treatment for IgG and IgA paraproteinaemic neuropathy.

Authors:  Abraham C J Stork; Michael P T Lunn; Eduardo Nobile-Orazio; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2015-03-24

10.  Polyneuropathy associated with IgA paraproteinemia and amyloidosis: a case report and literature review.

Authors:  Yunsook Jhang; Jung Ju Lee; Jong-Moo Park; Ja-Seong Koo; Byung-Kun Kim; Ohyun Kwon
Journal:  J Clin Neurol       Date:  2007-06-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.